Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody ; day:6 ; month:9 ; year:2016 ; pages:1-3
Investigational new drugs ; (6.9.2016), 1-3
- Creator
-
Mamesaya, Nobuaki
- Contributor
-
Kenmotsu, Hirotsugu
Katsumata, Mineo
Nakajima, Takashi
Endo, Masahiro
Takahashi, Toshiaki
SpringerLink (Online service)
- DOI
-
10.1007/s10637-016-0389-9
- URN
-
urn:nbn:de:1111-2016100611354
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mamesaya, Nobuaki
- Kenmotsu, Hirotsugu
- Katsumata, Mineo
- Nakajima, Takashi
- Endo, Masahiro
- Takahashi, Toshiaki
- SpringerLink (Online service)
Other Objects (12)
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
Drug induced interstitial lung disease
Respiratory bronchiolitis-interstitial lung disease
Interstitial lung diseases in children
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical Atlas of Interstitial Lung Disease
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
Drug induced interstitial lung disease
Respiratory bronchiolitis-interstitial lung disease
Interstitial lung diseases in children
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical Atlas of Interstitial Lung Disease
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
Drug induced interstitial lung disease
Respiratory bronchiolitis-interstitial lung disease
Interstitial lung diseases in children
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma